All In Biotech

Drug Trial Radar · NCT01854918

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145

Last checked: Nov 20, 2026Latest source record: Jun 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,681 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,681

Actual

Start

Apr 23, 2013

Primary completion

May 31, 2018

Study completion May 31, 2018

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
May 16, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.

Conditions

  • Hyperlipidemia and Mixed Dyslipidemia

Interventions

  • EvolocumabBiological

    Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen

  • Standard of CareDrug

    Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: 48 weeks in the SOC-controlled period and up to 2 years in the All-IP period

Locations

363 sites in 25 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Chandler, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Beverly Hills, California

  • Research Site

    Carmichael, California

  • Research Site

    Encinitas, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Mission Viejo, California

  • Research Site

    Newport Beach, California

  • Research Site

    San Diego, California

  • Research Site

    Santa Ana, California

  • Research Site

    Santa Rosa, California

  • Research Site

    Spring Valley, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Torrance, California

  • Research Site

    Tustin, California

  • Research Site

    Ventura, California

  • Research Site

    Littleton, Colorado

  • Research Site

    Daytona Beach, Florida

  • Research Site

    DeLand, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Melbourne, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Ponte Vedra, Florida

  • Research Site

    Port Charlotte, Florida

  • Research Site

    Sanford, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Gainesville, Georgia

  • Research Site

    Savannah, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Sterling, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Munster, Indiana

Showing 40 of 363 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.